The activity of a PI3K δ-sparing inhibitor, MEN1611, in non-small cell lung cancer cells with constitutive activation of the PI3K/AKT/mTOR pathway

The activity of a PI3K δ-sparing inhibitor, MEN1611, in non-small cell lung cancer cells with constitutive activation of the PI3K/AKT/mTOR pathway

BackgroundLung cancer remains the leading cause of cancer-related death worldwide. Targeted therapies with tyrosine kinase inhibitors (TKIs) result in improvement in survival for non-small cell lung cancer (NSCLC) with activating mutations of the epidermal growth factor receptor (EGFR). Unfortunatel...

Full description

Bibliographic Details
Main Authors: Giuliana Papoff, Dario Presutti, Valentina Fustaino, Andrea Parente, Clelia Calandriello, Stefano Alemà, Ferdinando Scavizzi, Marcello Raspa, Giuseppe Merlino, Massimiliano Salerno, Mario Bigioni, Monica Binaschi, Giovina Ruberti
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Oncology
Subjects:
NSCLC
PI3K inhibitor
EGFR-TKIs
drug-resistance
combination therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1283951/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1283951/full

Similar Items